Acetyl hexapeptide-38 1400634-44-7

99% up by HPLC

Inquire now

Product categories

New Products

Product Details

Product Information

Product name	Acetyl hexapeptide-38
CAS No.	1400634-44-7
Sequence	Ac-Ser-Val- Val -Val -Arg-Trp-NH2
Molecular Weight	701.82
Quality Standard	98% up by HPLC
Appearance	White or off-white powder

COA

Test Items	Specifications	Results
Appearance	White or off-white powder	White powder
Water	≤ 8.0%	6.8%
Acetic acid content	≤ 15.0%	0.96%
Purity	≥ 98.0%	99.6%
Conclusion	It conforms to the corporate Inner Quality Standards.

Usage

Acetyl Hexapeptide-38 is a top-tier synthetic peptide renowned in skincare for its exceptional anti-wrinkle efficacy, often described as a "biosimilar botox" alternative.

Key Efficacy of Acetyl Hexapeptide-38 - Targeted Wrinkle Reduction

Acetyl Hexapeptide-38 works by mimicking the body's own regulatory mechanisms to combat wrinkles at their source. Acetyl Hexapeptide-38 specifically targets the SNARE complex, a key protein machinery that mediates neurotransmitter release. Its fundamental principle of action involves functioning as a competitive inhibitor by structurally mimicking components of the SNARE assembly site, thereby precisely disrupting its formation. The resultant effect is a significant reduction in excessive acetylcholine release—the neurotransmitter responsible for muscle contraction—which subsequently leads to relaxation of facial expression muscles and diminished formation of movement-induced wrinkles.

2. Primary Skincare Benefits of Acetyl Hexapeptide-38

Benefit	Description
Smoothes Dynamic Wrinkles	Specifically targets and improves crow's feet, forehead lines, and frown lines caused by repeated muscle movement.
Prevents Static Wrinkles	Long-term use helps prevent dynamic wrinkles from becoming permanent static lines.
Gentle & Reversible	It is not a neurotoxin. Its action is mild, does not cause facial stiffness, and is reversible upon discontinuation.
Potent Performance	Clinically tested to demonstrate strong wrinkle-reducing efficacy, often outperforming many traditional peptides.

3. Application of Acetyl Hexapeptide-38

Acetyl Hexapeptide-38 primarily used in high-end anti-aging formulations:

✅ Serums

✅ Face Creams / Eye Creams

✅ Ampoules / Intensive Treatments

Summary:

✅ Precise Efficacy: Acts upstream in the neuromuscular signaling pathway for high efficiency.

✅ High Safety: Topical application is non-invasive and avoids injection-related risks.

✅ Advanced Technology: The complex production process represents a high technological barrier in cosmetic science.

Hot Tags : 1400634-44-7 Acetyl hexapeptide-38 Acetyl hexapeptide cosmetic peptide Acetyl hexapeptide powder Acetyl hexapeptide China

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Subject : Acetyl hexapeptide-38 1400634-44-7

Related Products

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.